

LAVOISIER HYDROS G 5 % - HYDROS G 10 %, injectable solution for infusion

QUALITATIVE AND QUANTITATIVE COMPOSITION

SPECIALTY	HYDROS G 5	HYDROS G 10
ANHYDROUS GLUCOSE	5.0 g	10.0 g
SODIUM CHLORIDE	0.40 g	0.40 g
POTASSIUM CHLORIDE	0.20 g	0.20 g
Water for injectable solutions s.q.	100 ml	100 ml
Na ⁺	68.4 mEq/l	68.4 mEq/l
K ⁺	26.8 mEq/l	26.8 mEq/l
Cl ⁻	95.2 mEq/l	95.2 mEq/l
Glucose	277.5 mOsm/l	555.0 mOsm/l
OSMOLARITY	467.9 mOsm/l	745.4 mOsm/l

pH ranging from 3.5 to 5.0

PHARMACEUTICAL FORM

Injectable solution

THERAPEUTIC INDICATIONS

- Moderate caloric glucose intake (**HYDROS G 5**: 200 Kcal/l. - **HYDROS G 10**: 400 Kcal/l.)
- Rebalance of electrolytes (with potassium and sodium chloride supplements) depending on clinical evaluations and ions concentration in blood and urine tests

POSOLOGY AND ADMINISTRATION

The physician will determine the posology depending on patient's clinical state and laboratory determinations.

Administration route: slow intravenous infusion.

Contra-indications

Sodium retention.
Hyperkalemia.

WARNINGS AND PRECAUTIONS FOR USE

- Decision whether to use this solution is determined by careful examination of clinical data and laboratory tests.
- This injectable solution should be used with great care with regard to the volume of liquid and amount of electrolytes administered.
- Risk of overload on the cardiovascular system with pulmonary oedema especially in predisposed subjects.
- To be used with extreme caution in patients with: congestive cardiac insufficiency, severe renal failure, oedema with sodium retention and treatment with corticoids and their derivatives.
- This solution is content-potassium and should be used cautiously in patients with hyperkalemia or severe renal failure.
- Patient's clinical monitoring and laboratory tests should be performed (electrolyte assessments in blood and urine) with possible dose adjustment of Loop diuretics in diabetics.
- Slow infusion with strict asepsis
- Injection should not be given by I.M. route

CLINICAL PHARMACOLOGY

Pharmacodynamics

GLUCOSE SUPPLEMENT PRODUCTS / VOLEMIC REPLACEMENT
(B: hematopoietic stem cells blood and lymphoid organs)
Solution used for vascular filling and electrolyte rebalance.

Pharmacokinetics

Drug metabolism is that of glucose and the different ions (Na⁺, K⁺ and Cl⁻).

PHARMACEUTICAL DATA

Incompatibilities

- The physician will determine the incompatibilities of an additive drug with **LAVOISIER HYDROS G 5** or **G 10** inspecting for possible discoloration and/or formation of precipitate, insoluble complex or crystals. Refer also to package insert of the drug to be added.
- Prior to drug admixture, check whether its pH efficacy space matches that of **LAVOISIER HYDROS G 5** or **G 10** (pH = 3.5 TO 5.0).
- If a drug is added to LAVOISIER HYDROS G 5 or G 10, mixture must be administered immediately, except if stored frozen.

Shelf life: 3 years

Nature and contents of container

500 ml or 1000 ml bottle, colorless glass (type II), closed with a chlorobutyl stopper.

Instructions for use, Drug handling instruction

Prior to use, inspect for limpidity, physical integrity of bottle (check for cracks...), closures and vacuum state (water hammer test).

PACKAGING AND PRODUCT LICENSE NUMBER

Hospital Packaging:

LAVOISIER HYDROS G 5

MA 558 153-3: 500 ml bottle (glass) - 12 units pack - Approved for institutions

MA 558 156-2: 1000 ml bottle (glass) - 6 units pack - Approved for institutions.

LAVOISIER HYDROS G 10

MA 558 158-5: 500 ml bottle (glass) - 12 units pack - Approved for institutions

MA 558 161-6: 1000 ml bottle (glass) - 6 units pack - Approved for institutions

HOW SUPPLIED

Check the compatibility of additive drugs with container.

REVISION OF DATE: October 2000

CDM LAVOISIER

Laboratoires Chaix et Du Marais - 7, rue Labie - 75017 PARIS - FRANCE

Tel: +33 1 55 37 83 83

E-mail: contact@lavoisier.com

Fax: +33 1 55 37 83 84